Marvin Woodall

Mr. Woodall's distinguished career at Johnson & Johnson spanned nearly 37 years, where he retired in 2001. He served as the President of Johnson & Johnson Interventional Systems, Inc., leading the team responsible for pioneering its multibillion-dollar cardiovascular franchise.

His tenure at J&J included the development and launch of the transformational PALMAZ-SCHATZ® Coronary Stent and development of the world’s first drug eluting stent. Mr. Woodall, while at Johnson & Johnson, was subsequently responsible for Health Economics Worldwide, for the Cordis circulatory disease business franchise.

He has served as the Chairman, or CEO or Board member of the Lehigh Valley Hospital and Health Network, Doylestown Hospital, the Cardiovascular Research Foundation, the International Society of Endovascular Specialists, Icon Interventional Systems, Inc., Prescient Medical, Inc., Spectranetics, CardioMEMs, Inc., Contego Medical, LLC, and Percutaneous Valve Technologies, Inc. plus several community based non-profit entities, including the Free Clinic of Doylestown, the Heritage Conservancy, Looking Ahead LLC, and the Playhouse Artists of the Bucks County Theater.

He received his undergraduate degree with a B.B.A. in Management and Finance from the University of Oklahoma and he completed graduate studies at Harvard, Columbia, and Duke Universities.